Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Speech-derived Digital Biomarkers for Assessing Mild Cognitive Impairment and Alzheimer's Disease Diagnosis Accuracy

NCT06994767 is registered in ClinicalTrials.gov with Hackensack Meridian Health as lead sponsor.

NCT NCT06994767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06994767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Speech-derived Digital Biomarkers for Assessing Mild Cognitive Impairment and Alzheimer's Disease Diagnosis Accuracy
Lead sponsor
Hackensack Meridian Health
Phase
Not applicable
Overall status
Completed
Start date
May 19, 2025
Completion date
January 9, 2026
Enrollment
150 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, mild cognitive impairment (mci)